| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| APALUTAMIDE (has an active metabolite)
| APALUTAMIDE | ANTINEOPLASTIC | ORAL | Cmax 12.5 MICROMOLAR Tmax 3 HOUR F 100 PERCENT VD 276 LITER PPB 96 PERCENT Cl 1.3 LITER / HOUR HT 72 HOUR SOLUBILITY PRACTICALLY INSOLUBLE IN AQUEOUS MEDIA OVER A WIDE RANGE OF PH VALUES | ANDROGEN RECEPTOR | NUCLEAR RECEPTOR ANDR_HUMAN INHIBITOR P10275 | ANSM (in French) | |||
| 2 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| M APALUTAMIDE (is an active metabolite)
| APALUTAMIDE | ANTINEOPLASTIC | - | Cmax 12.7 MICROMOLAR PPB 95 PERCENT | ANDROGEN RECEPTOR | NUCLEAR RECEPTOR ANDR_HUMAN INHIBITOR P10275 | ANSM (in French) | |||
